The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors

 The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors

Concomitant medications are emerging as a modifiable prognostic factor for immune checkpoint inhibitor treatment outcomes. This Review by Stone et al. highlights the potential immunomodulatory interactions of commonly prescribed medications and supplements, a…

  • Powles, T. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med.383, 12181230 (2020).
    CAS 
    PubMed 
    Google Scholar 
  • Shen, L. et al. Ti…